Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbrella Study in R/R PTCL Guided by Molecular Subtypes
NCT05559008Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine, dasatinib, linperlisib, tucidinostat, zeprumetostat and 2 more in peripheral T-cell lymphoma (PTCL) (4 arms), sponsored by Ruijin Hospital. Primary endpoint: Overall Response Rate. Started Sep 2022; status: recruiting.
02
Drugs
azacitidinedasatiniblinperlisibtucidinostatzeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05559008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559008.